{"analyses":[{"ciLowerLimit":"-8.20","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"17.51","groupDescription":"Anetumab ravtansine versus vinorelbine","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.244","paramType":"Difference (%) improvement rate symptoms","paramValue":"4.65","statisticalComment":"1-sided Cochran-Mantel-Haenszel test, stratified by TTP on 1st line treatment","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.1","upperLimit":"31.4","value":"22.5"},{"groupId":"OG001","lowerLimit":"8.9","upperLimit":"30.4","value":"17.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"82"}],"units":"Participants"}],"description":"Improvement rate of symptoms characteristic of mesothelioma was defined as the number of patients with confirmed improvement of symptoms characteristic of mesothelioma (based on the MD Anderson Symptom Inventory-Malignant Pleural Mesothelioma, MDASI-MPM), divided by the number of patients evaluable for improvement of symptoms characteristic of mesothelioma.","dispersionType":"95% Confidence Interval","groups":[{"description":"Test drug: 6.5 mg/kg every 3 weeks; Intravenous (IV) infusion over 1 hour","id":"OG000","title":"Anetumab Ravtansine"},{"description":"Active comparator: 30 mg/m\\^2 once weekly","id":"OG001","title":"Vinorelbine"}],"paramType":"NUMBER","populationDescription":"The secondary efficacy analysis was performed in the ITT (Intent-to-treat) analysis set.","reportingStatus":"POSTED","timeFrame":"up to approx. 30 months (data cut-off: 31-May-2017)","title":"Percentage of Participants With Confirmed Improvement of Symptoms Characteristic of Mesothelioma","type":"SECONDARY","unitOfMeasure":"percentage of participants"}